ABT-335
Sponsors
Abbott, AstraZeneca, AbbVie (prior sponsor, Abbott)
Conditions
Adverse EventsCombined (Atherogenic) DyslipidemiaCoronary Artery DiseaseCoronary Heart DiseaseDyslipidemiaDyslipidemia, Renal InsufficiencyDyslipidemiasHealthy
Phase 1
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
CompletedNCT00585143
Start: 2008-01-31End: 2008-10-31Updated: 2012-09-28
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
CompletedNCT00681395
Start: 2008-05-31Updated: 2012-09-28
A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe
CompletedNCT00681525
Start: 2008-04-30Updated: 2010-10-19
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
CompletedNCT00808678
Start: 2008-12-31Updated: 2012-09-28
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
CompletedNCT00826358
Start: 2008-11-30Updated: 2012-09-28
Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules
CompletedNCT00839293
Start: 2009-02-28Target: 32Updated: 2010-10-15
Phase 3
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
CompletedNCT00300456
Start: 2006-03-31Updated: 2009-06-03
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
CompletedNCT00300482
Start: 2006-03-31Updated: 2009-06-10
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
CompletedNCT00300469
Start: 2006-03-31Updated: 2009-06-03
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
CompletedNCT00463606
Start: 2007-04-30End: 2008-02-29Updated: 2012-10-03
A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia
CompletedNCT00491530
Start: 2007-06-30End: 2008-11-30Updated: 2012-01-20
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
CompletedNCT00616772
Start: 2008-02-29End: 2012-09-30Updated: 2018-07-02
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
CompletedNCT00639158
Start: 2008-02-29Updated: 2011-06-13